Updated Jul 16, 2026
Koenig Sheldon L. has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $349K.
Sheldon L. Koenig is the President and CEO of Esperion Therapeutics, Inc., a pharmaceutical company focused on developing non-statin therapies for cholesterol management. He has also served as a director for the company, contributing to its strategic direction and growth.
| Role | President and CEO, Director |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-13 | ESPR | Esperion Therapeutics, Inc. | D — Derivative transaction | 2.12M | — | |
| 2026-06-18 | ESPR | Esperion Therapeutics, Inc. | S — Open-market sale | 53.6K | $3.15 | $169K |
| 2026-03-18 | ESPR | Esperion Therapeutics, Inc. | S — Open-market sale | 25.6K | $2.72 | $70K |
| 2026-03-16 | ESPR | Esperion Therapeutics, Inc. | A — Grant or award | 723.8K | $0.00 | |
| 2025-09-17 | ESPR | Esperion Therapeutics, Inc. | S — Open-market sale | 28.4K | $2.79 | $79K |
| 2024-12-18 | ESPR | Esperion Therapeutics, Inc. | S — Open-market sale | 12.4K | $2.47 | $31K |
Sheldon L. Koenig is the President and CEO of Esperion Therapeutics, Inc., a pharmaceutical company focused on developing non-statin therapies for cholesterol management. He has also served as a director for the company, contributing to its strategic direction and growth.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 4 open-market sales ($349K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Koenig Sheldon L. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.